Trial Profile
A Phase I Study of NX211 [OSI 211] Given as an IV Infusion Days 1, 2 and 3 Every 3 Weeks in Patients With Solid Tumors
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 13 Apr 2020
Price :
$35
*
At a glance
- Drugs OSI 211 (Primary)
- Indications Solid tumours
- Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
- 21 Sep 2013 Additional lead trial centre added as reported by ClinicalTrials.gov.
- 16 Mar 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 16 Mar 2010 Actual end date (Sep 2009) added as reported by ClinicalTrials.gov.